Seoul Pharma Statistics
Total Valuation
Seoul Pharma has a market cap or net worth of KRW 36.20 billion. The enterprise value is 43.74 billion.
Market Cap | 36.20B |
Enterprise Value | 43.74B |
Important Dates
Earnings Date | n/a |
Ex-Dividend Date | n/a |
Share Statistics
Seoul Pharma has 11.66 million shares outstanding.
Current Share Class | 11.66M |
Shares Outstanding | 11.66M |
Shares Change (YoY) | n/a |
Shares Change (QoQ) | n/a |
Owned by Insiders (%) | n/a |
Owned by Institutions (%) | n/a |
Float | 4.73M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | 0.69 |
PB Ratio | 0.94 |
P/TBV Ratio | 0.96 |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 18.85, with an EV/FCF ratio of -10.16.
EV / Earnings | -66.19 |
EV / Sales | 0.84 |
EV / EBITDA | 18.85 |
EV / EBIT | n/a |
EV / FCF | -10.16 |
Financial Position
The company has a current ratio of 1.99, with a Debt / Equity ratio of 0.46.
Current Ratio | 1.99 |
Quick Ratio | 1.04 |
Debt / Equity | 0.46 |
Debt / EBITDA | 7.71 |
Debt / FCF | -4.16 |
Interest Coverage | -0.75 |
Financial Efficiency
Return on equity (ROE) is -1.69% and return on invested capital (ROIC) is -0.38%.
Return on Equity (ROE) | -1.69% |
Return on Assets (ROA) | -0.29% |
Return on Invested Capital (ROIC) | -0.38% |
Return on Capital Employed (ROCE) | -0.59% |
Revenue Per Employee | 303.46M |
Profits Per Employee | -3.84M |
Employee Count | 172 |
Asset Turnover | 0.74 |
Inventory Turnover | 1.58 |
Taxes
Income Tax | -84.70M |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -16.37% in the last 52 weeks. The beta is 0.59, so Seoul Pharma's price volatility has been lower than the market average.
Beta (5Y) | 0.59 |
52-Week Price Change | -16.37% |
50-Day Moving Average | 3,286.70 |
200-Day Moving Average | 3,350.73 |
Relative Strength Index (RSI) | 28.68 |
Average Volume (20 Days) | 7,441 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Seoul Pharma had revenue of KRW 52.20 billion and -660.90 million in losses. Loss per share was -56.68.
Revenue | 52.20B |
Gross Profit | 31.83B |
Operating Income | -329.39M |
Pretax Income | -745.60M |
Net Income | -660.90M |
EBITDA | 2.32B |
EBIT | -329.39M |
Loss Per Share | -56.68 |
Balance Sheet
The company has 10.36 billion in cash and 17.90 billion in debt, giving a net cash position of -7.54 billion or -646.88 per share.
Cash & Cash Equivalents | 10.36B |
Total Debt | 17.90B |
Net Cash | -7.54B |
Net Cash Per Share | -646.88 |
Equity (Book Value) | 38.68B |
Book Value Per Share | 3,317.27 |
Working Capital | 17.18B |
Cash Flow
In the last 12 months, operating cash flow was -2.98 billion and capital expenditures -1.32 billion, giving a free cash flow of -4.31 billion.
Operating Cash Flow | -2.98B |
Capital Expenditures | -1.32B |
Free Cash Flow | -4.31B |
FCF Per Share | -369.24 |
Margins
Gross margin is 60.98%, with operating and profit margins of -0.63% and -1.27%.
Gross Margin | 60.98% |
Operating Margin | -0.63% |
Pretax Margin | -1.43% |
Profit Margin | -1.27% |
EBITDA Margin | 4.45% |
EBIT Margin | -0.63% |
FCF Margin | n/a |
Dividends & Yields
Seoul Pharma does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | n/a |
Shareholder Yield | n/a |
Earnings Yield | -1.83% |
FCF Yield | -11.89% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
Lynch Fair Value | n/a |
Lynch Upside | n/a |
Graham Number | n/a |
Graham Upside | n/a |
Stock Splits
The last stock split was on April 12, 2004. It was a forward split with a ratio of 2.
Last Split Date | Apr 12, 2004 |
Split Type | Forward |
Split Ratio | 2 |
Scores
Seoul Pharma has an Altman Z-Score of 1.78 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
Altman Z-Score | 1.78 |
Piotroski F-Score | 1 |